- Home
- BNR vs PULM Comparison
BNR vs PULM Comparison
Compare BNR & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNR
- PULM
- Stock Information
- Founded
- BNR 2014
- PULM 2003
- Country
- BNR China
- PULM United States
- Employees
- BNR N/A
- PULM N/A
- Industry
- BNR Medical Specialities
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- BNR Health Care
- PULM Health Care
- Exchange
- BNR Nasdaq
- PULM Nasdaq
- Market Cap
- BNR 38.3M
- PULM 20.5M
- IPO Year
- BNR 2020
- PULM N/A
- Fundamental
- Price
- BNR $6.13
- PULM $5.48
- Analyst Decision
- BNR
- PULM
- Analyst Count
- BNR 0
- PULM 0
- Target Price
- BNR N/A
- PULM N/A
- AVG Volume (30 Days)
- BNR 53.5K
- PULM 11.7K
- Earning Date
- BNR 08-21-2025
- PULM 08-12-2025
- Dividend Yield
- BNR N/A
- PULM N/A
- EPS Growth
- BNR N/A
- PULM N/A
- EPS
- BNR N/A
- PULM N/A
- Revenue
- BNR $72,112,038.00
- PULM $1,921,000.00
- Revenue This Year
- BNR $136.32
- PULM N/A
- Revenue Next Year
- BNR N/A
- PULM $134.88
- P/E Ratio
- BNR N/A
- PULM N/A
- Revenue Growth
- BNR 0.53
- PULM N/A
- 52 Week Low
- BNR $2.18
- PULM $1.78
- 52 Week High
- BNR $9.48
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- BNR 56.55
- PULM 28.72
- Support Level
- BNR $6.71
- PULM $5.60
- Resistance Level
- BNR $9.48
- PULM $6.15
- Average True Range (ATR)
- BNR 0.85
- PULM 0.29
- MACD
- BNR 0.17
- PULM -0.08
- Stochastic Oscillator
- BNR 34.46
- PULM 4.29
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).